Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock performance was -6.80% in last session and finished the day at $24.27. Traded volume was 3.59million shares in the last session and the average volume of the stock remained 1.80million shares. The beta of the stock remained 3.02. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider ownership is 0.10%.

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Incyte Corporation (NASDAQ:INCY) was identified as having a larger market cap than the smaller end of the S&P 500, for example Molson Coors Brewing Co. (TAP), according to The Online Investor. Incyte Corporation (NASDAQ:INCY) dropped -6.24 percent to $55.70 Monday on volume of 3.43million shares. The intra-day range of the stock was $53.23 to $59.77. Incyte Corporation (NASDAQ:INCY) has a market capitalization of $9.22billion.

Analysts at MLV & Co. cut their price objective on shares of Galena Biopharma Inc (NASDAQ:GALE) from $6.00 to $5.00 in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports.MLV & Co.‘s target price indicates a potential upside of 71.23% from the stock’s previous close. Galena Biopharma Inc (NASDAQ:GALE)’s stock on Mar 24, 2014 reported a decrease of -7.53% to the closing price of $2.70. Its fifty two weeks range is $1.65 -$7.77. The total market capitalization recorded $318.27million. The overall volume in the last trading session was 5.84million shares. In its share capital, GALE has 106.69million outstanding shares.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is still a top stock to buy at many Wall Street firms, and some consider it a potential acquisition target. Some analysts see likely strong accretive near-term to an acquirer, given the very impressive $1.5 billion revenues, which are big enough to be significant to a larger company. On Monday, shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) dropped -6.28% to close the day at $149.76. Company return on investment (ROI) is 10.20% and its monthly performance is recorded as -17.50%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) quarterly revenue growth is 14.54%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone